TheraRadar
Clinical-Stage Companies / Cinnagen

Cinnagen

Pre-Approval PRO BETA
đź”´

Stale Activity

No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 9/10/2022

15
Total Trials
12
Phase 3
1
Phase 2
0
Recruiting
194
Score

Pipeline by Phase

Phase 3
12
Phase 2
1
Phase 1
2

Therapeutic Focus

COVID-19 Covid19 Bioequivalence Mucopolysaccharidosis Type 1 HER2-positive Breast Cancer

Clinical Trials (15)

NCT06406153 Phase 3 COMPLETED

Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients

Started: 9/10/2022

NCT04957212 Phase 3 COMPLETED

Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

Started: 8/11/2018

NCT03223025 Phase 3 COMPLETED

Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency

Started: 3/9/2016

NCT05813470 Phase 3 COMPLETED

Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma

Started: 1/18/2021

NCT05587062 Phase 3 COMPLETED

Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Started: 10/1/2019

NCT05242133 Phase 3 COMPLETED

Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis

Started: 12/20/2017

NCT04966338 Phase 3 COMPLETED

Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis

Started: 8/19/2019

NCT05231590 Phase 3 COMPLETED

Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years Compared With Adults Aged 18 to 40 Years

Started: 2/23/2022

NCT05175625 Phase 3 COMPLETED

Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine

Started: 12/15/2021

NCT05005559 Phase 3 COMPLETED

Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

Started: 8/7/2021

NCT03172325 Phase 3 COMPLETED

Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA

Started: 11/18/2015

NCT03408639 Phase 3 COMPLETED

Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients

Started: 6/22/2016

NCT04944368 Phase 2 COMPLETED

Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

Started: 5/30/2021

NCT03614715 Phase 1 COMPLETED

Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)

Started: 11/27/2017

NCT03273192 Phase 1 COMPLETED

A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects

Started: 10/22/2016

Drug Candidates

Laronidase Antihistamine Antipyretic Trastuzumab Pertuzumab Carboplatin Docetaxel CinnaTropin® Nordilet® Omalizumab (CinnaGen)
Activity Status: Stale
Last Trial Started: 9/10/2022
Last Trial Ended: 11/18/2023
Trials (12 months): 0
Completed Trials: 15
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.